Metformin Ennogen Ip

Active Ingredient:: Metformin
Origin:: EU

Metformin Ennogen Ip (Metformin)

Q: What is Metformin Ennogen Ip used for?

Metformin Ennogen Ip is a Biguanide indicated for the treatment of type 2 diabetes mellitus. It helps lower blood glucose by reducing liver glucose production and improving insulin sensitivity in peripheral tissues.

Q: How does Metformin work in the body?

Metformin acts primarily by inhibiting hepatic gluconeogenesis, which decreases the amount of glucose released into the bloodstream. It also enhances peripheral glucose uptake and modestly reduces intestinal glucose absorption, leading to improved glycemic control.

Q: What is the usual dose of Metformin Ennogen Ip?

The dosage of Metformin Ennogen Ip is individualized by the prescribing clinician based on the patient’s clinical condition, renal function, and response to therapy. The prescriber determines the appropriate strength and dosing schedule.

Q: Is Metformin safe during pregnancy or breastfeeding?

Metformin may be used during pregnancy or lactation only when clearly needed and after a risk‑benefit assessment by the healthcare provider. Women who are pregnant, planning pregnancy, or breastfeeding should discuss potential risks with their clinician.

Q: How do I order Metformin Ennogen Ip from GNH India?

To place an order, submit an enquiry on the product page at gnhindia.com with the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Q: How does Metformin compare with other antidiabetic drugs?

Metformin is often preferred as first‑line therapy for type 2 diabetes because it does not cause weight gain and has a low risk of hypoglycemia compared with sulfonylureas or insulin. Its mechanism differs from DPP‑4 inhibitors or SGLT2 inhibitors, offering a complementary option in combination regimens.

Q: What are the storage and handling requirements for Metformin Ennogen Ip?

Metformin Ennogen Ip should be stored at ambient temperature, below 25 °C, in its original packaging. Protect the product from moisture, direct sunlight, and excessive heat to maintain its stability.

Q: How is Metformin Ennogen Ip administered?

Metformin Ennogen Ip is taken orally, usually with meals to reduce gastrointestinal discomfort. The tablet should be swallowed whole with a glass of water and not crushed or chewed unless specifically instructed by a healthcare professional.

Q: What are the most serious risks associated with Metformin?

The most serious risk is lactic acidosis, a rare but potentially fatal condition that can occur in patients with severe renal or hepatic impairment, or after exposure to iodinated contrast media. Prompt medical attention is required if symptoms such as rapid breathing, muscle pain, or abdominal discomfort develop.

Q: Who should not use Metformin Ennogen Ip?

Metformin is contraindicated in patients with severe renal impairment (eGFR <30 mL/min/1.73 m²), acute or chronic hepatic disease, a history of lactic acidosis, or those undergoing radiographic procedures using iodinated contrast agents without appropriate discontinuation.

Metformin, the active ingredient in Metformin Ennogen Ip, is a Biguanide presented as an oral formulation for Oral use. It treats type 2 diabetes mellitus in adults by improving blood‑sugar control.

GNH India supplies Metformin Ennogen Ip as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Manufacturer / TM Owner

Ennogen Ip Limited

Select Quantity

Pack/s

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

First Name

Last Name

Phone

Delivery Country

Delivery PostCode/Zipcode

Select Your Profile

I have read and agree to the terms & conditions, including the privacy policy, return policy, and usage terms as applicable to this request.

Indications & Clinical Uses

Metformin is used in the management of disorders related to glucose metabolism and insulin resistance.
Type 2 diabetes mellitus: lowers fasting plasma glucose and HbA1c to improve glycemic control.
Gestational diabetes mellitus: may be prescribed when diet alone is insufficient, under medical supervision.
Polycystic ovary syndrome: can improve insulin sensitivity and help regulate menstrual cycles when indicated by a clinician.

How It Works

Metformin primarily inhibits hepatic gluconeogenesis, reducing the amount of glucose released by the liver. It also enhances peripheral glucose uptake by increasing insulin sensitivity in muscle and adipose tissue, and modestly decreases intestinal absorption of glucose, collectively contributing to lower blood‑sugar levels.

Side Effects

Metformin may cause a range of adverse reactions, from mild to serious.

Common Side Effects

Nausea: transient stomach upset that often resolves with continued use.
Diarrhea: loose stools, usually mild to moderate.
Abdominal discomfort: cramping or pain in the stomach area.
Metallic taste: a transient metallic sensation in the mouth.
Loss of appetite: reduced desire to eat.
Flatulence: increased gas production.

Serious or Rare Side Effects

Lactic acidosis: a rare but life‑threatening buildup of lactic acid.
Severe skin reactions: such as Stevens‑Johnson syndrome.
Hepatic dysfunction: abnormal liver enzyme elevations.
Hypoglycemia: especially when combined with other glucose‑lowering agents.
Vitamin B12 deficiency: may develop with long‑term therapy.
Acute pancreatitis: inflammation of the pancreas.

Precautions & Warnings

Metformin requires careful consideration of patient‑specific factors before initiation.
Renal function assessment: avoid use in severe renal impairment (eGFR <30 mL/min/1.73 m²).
Liver disease monitoring: contraindicated in acute or chronic hepatic failure.
Risk of lactic acidosis: discontinue before any radiographic contrast studies.
Vitamin B12 monitoring: periodic testing recommended for long‑term therapy.
Alcohol consumption: limit intake to reduce lactic acidosis risk.
Store at ambient temperature: keep in the original pack, protect from moisture and heat.

Avoid Interactions

Metformin can interact with several medicines, altering its efficacy or safety.

Major Interactions (Avoid)

Iodinated contrast agents: may precipitate lactic acidosis; hold metformin before and after use.
Cimetidine: can increase metformin plasma concentrations.
Alcohol: potentiates risk of lactic acidosis.
Diuretics (loop or thiazide): may impair renal function, raising metformin levels.
Nifedipine: may increase metformin exposure.

Moderate Interactions (Monitor Closely)

Sulfonylureas: combined therapy raises hypoglycemia risk.
Beta‑blockers: may mask hypoglycemia symptoms.
ACE inhibitors/ARBs: monitor renal function and electrolytes.
Warfarin: may affect INR stability.
Digoxin: watch for altered serum concentrations.

Frequently Asked Questions

Metformin Ennogen Ip is a Biguanide indicated for the treatment of type 2 diabetes mellitus. It helps lower blood glucose by reducing liver glucose production and improving insulin sensitivity in peripheral tissues.

Metformin acts primarily by inhibiting hepatic gluconeogenesis, which decreases the amount of glucose released into the bloodstream. It also enhances peripheral glucose uptake and modestly reduces intestinal glucose absorption, leading to improved glycemic control.

The dosage of Metformin Ennogen Ip is individualized by the prescribing clinician based on the patient’s clinical condition, renal function, and response to therapy. The prescriber determines the appropriate strength and dosing schedule.

Metformin may be used during pregnancy or lactation only when clearly needed and after a risk‑benefit assessment by the healthcare provider. Women who are pregnant, planning pregnancy, or breastfeeding should discuss potential risks with their clinician.

To place an order, submit an enquiry on the product page at gnhindia.com with the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Metformin is often preferred as first‑line therapy for type 2 diabetes because it does not cause weight gain and has a low risk of hypoglycemia compared with sulfonylureas or insulin. Its mechanism differs from DPP‑4 inhibitors or SGLT2 inhibitors, offering a complementary option in combination regimens.

Metformin Ennogen Ip should be stored at ambient temperature, below 25 °C, in its original packaging. Protect the product from moisture, direct sunlight, and excessive heat to maintain its stability.

Metformin Ennogen Ip is taken orally, usually with meals to reduce gastrointestinal discomfort. The tablet should be swallowed whole with a glass of water and not crushed or chewed unless specifically instructed by a healthcare professional.

The most serious risk is lactic acidosis, a rare but potentially fatal condition that can occur in patients with severe renal or hepatic impairment, or after exposure to iodinated contrast media. Prompt medical attention is required if symptoms such as rapid breathing, muscle pain, or abdominal discomfort develop.

Metformin is contraindicated in patients with severe renal impairment (eGFR <30 mL/min/1.73 m²), acute or chronic hepatic disease, a history of lactic acidosis, or those undergoing radiographic procedures using iodinated contrast agents without appropriate discontinuation.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated: 05 Sep 2026

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.